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 Australian strains of Streptococcus suis have not evolved significantly from overseas 
strains 
 Australian ST1 strains carry a broader range of putative virulence factors than other 
strains 
 Australian ST1 strains have significantly smaller genome sizes than other strains 
 Australian clones associated with disease in pigs consist predominantly of serotypes 
2, 3 and ½ 
 Australian strains have a high prevalence of resistance to tetracycline and 
erythromycin. 
 A low level of resistance to penicillin (8.1%) was seen, however all isolates were 




Streptococcus suis is a major zoonotic pathogen that causes severe disease in both humans 
and pigs. Australia’s pig herd has been quarantined for over 30 years, however S. suis 
remains a significant cause of disease. In this study, we investigated S. suis from 148 cases of 
clinical disease in pigs from 46 pig herds over a period of seven years, to determine the level 
of genetic difference from international isolates that may have arisen over the 30 years of 
separation. Isolates underwent whole genome sequencing, genome analysis and antimicrobial 
susceptibility testing. Data was compared at the core genome level to clinical isolates from 
overseas. Results demonstrated five predominant multi-locus sequence types and two major 
cps gene types (cps2 and 3). At the core genome level Australian isolates clustered 
predominantly within one large clade consisting of isolates from the UK, Canada and North 
America. A small proportion of Australian swine isolates (5%) were phylogenetically 
associated with south-east Asian and UK isolates, many of which were classified as causing 
systemic disease, and derived from cases of human and swine disease. Based on this dataset 
we provide a comprehensive outline of the current S. suis clones associated with disease in 
Australian pigs and their global context, with the main finding being that, despite three 













addition, we show that ST1 clones carry a constellation of putative virulence genes not 
present in other Australian STs.  
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Streptococcus suis is an agent of serious concern for the global swine industry, and an 
emerging zoonotic agent causing meningitis, sepsis, arthritis, endocarditis and endopthalmitis 
in humans. In swine, S. suis is predominantly carried on the tonsils, but also within nasal 
cavities, genital and gastrointestinal tracts of many clinically healthy pigs, a feature which 
complicates management strategies in herds with disease outbreaks. Despite this carriage in 
healthy pigs, S. suis is a cause of a wide range of clinical syndromes ranging from sudden 
death in the peracute manifestation of disease, to meningitis, septicaemia, endocarditis, 
arthritis and pneumonia. The clinical manifestations generally occur in the post-weaning 
period, although can occur less frequently in suckers and in adult pigs (Gottschalk, 2011). 
Isolates obtained from areas indicative of invasive disease such as joints, brain tissue, heart 
and abdomen may be referred to as systemic, or causative of systemic infection, in contrast to 
isolates obtained from lung tissue.  
Human disease is particularly prevalent in the western Pacific and south-east Asian regions, 
where risk is predominantly attributable to poor sanitation at slaughter and ingestion of 
undercooked pork, followed by Europe and then significantly less in the Americas (Huong et 
al., 2014). Zoonotic infection with S. suis has occurred in Australia, although there are few 













abattoir worker from Victoria and two piggery workers from New South Wales respectively 
(Kennedy et al., 2008; Tramontana et al., 2008) with each case attributed to serotype 2, 
which, along with serotype 14, is one of two globally-dominant serotypes detected in human 
cases. 
Treatment for affected pigs is usually reliant on administration of β-lactams such as penicillin 
and amoxicillin, and, where permitted, farms may prophylactically treat all pigs at the peri-
weaning stage. Another management option employed by some producers is vaccination, 
usually in the form of bacterins produced as autogenous vaccines from on-farm isolates 
(Varela et al., 2013). Due to the highly variable antigenicity of the capsular polysaccharides 
(CPS), S. suis is currently classified into 29 serotypes (six previously classified serotypes 
have been reassigned to different bacterial species) (Tien le et al., 2013), and it is considered 
that protection (if any) is only provided by homologous vaccine serotypes. In addition to this, 
virulence factors and yet to be determined genetic factors may play a role in poor vaccine 
efficacy (Segura, 2015), although virulence factors are not necessarily protective antigens and 
the current uncertainty surrounding the role of virulence factors makes this difficult to assess. 
A recent review on the worldwide distribution and typing of S. suis provided a 
comprehensive analysis of the predominant serotypes and MLSTs in swine production 
systems across the US, South America, Europe and South-East Asia (Goyette-Desjardins et 
al., 2014). Of note in this review was the lack of information on Australian S. suis types, with 
no published surveillance since 1994 (Mwaniki et al., 1994), a gap of 20 years. Following 
this a study published in 2015 on 45 Australian S. suis isolates (encompassing 3 human 
isolates from 2006-2008, and 42 swine isolates from 1981-2011) described 4 MLST’s (1, 25, 
369 and 28) (Groves et al., 2015). 
Given the paucity of data available on S. suis associated with disease in Australian pigs, the 













diseased pigs obtained across multiple production sites and spanning a seven year period. 
Australia has not imported pigs for over 30 years (Todd, 1988), and has strong regulations 
which exclude the use of critically important antimicrobials in Australian livestock, for 
example prohibiting the use of fluoroquinolones (Abraham et al., 2017). Given the level of 
genetic diversity in S. suis, it was hypothesised that Australian isolates would form a subset 
which has diverged significantly from those overseas. Following this hypothesis, Australian 
strains would be expected to have modified putative virulence genes due to independent 
evolution as a result of geographic isolation and potentially different targets for vaccine 
development. Additionally antimicrobial resistance profiles are hypothesised to differ due to 
acquisition of distinct antimicrobial resistance determinants with the unique selection 
pressures in the Australian livestock sector. In this study, we report on virulence factors and 
antimicrobial susceptibility, and compare the core genome to international isolates to assess 




A total of 148 swabs from archived clinical isolates were transferred from ACE Laboratory 
Services (a major swine-industry referral lab) to the Murdoch University Antimicrobial 
Resistance and Infectious Diseases Laboratory for detailed molecular analysis. The majority 
of isolates were acquired from the lungs of diseased pigs and were classified as potentially 
virulent, followed by isolates from heart, brain, abdomen and joints, which were classified as 
virulent isolates, and miscellaneous sites including upper respiratory tract, abscesses and 
lymphoid tissue (Table 1). Isolates spanned a seven year period with 2, 1, 29, 27, 9, 49 and 29 
isolates from years 2010, 2011, 2013, 2014, 2015, 2016 and 2017 respectively, and two 













Australia’s major pig production enterprises (17 samples were of unknown origin) and 
encompassed 46 known individual farms (7 isolates had unavailable farm data). Of the 
available farm data, 39 farms accounted for between one and five isolates each, five farms 
accounted for between six and eight isolates each and one farm accounted for 33 isolates.  
Isolates.  
Swabs or fresh tissue from diseased pigs were submitted by consultant veterinarians to ACE 
Laboratory Service, Victoria, Australia. Samples were plated onto Sheep Blood Agar (SBA), 
MacConkey Agar and Chocolate Agar (Oxoid, Thermo Fisher Scientific), and incubated at 
37°C for 24 hours. Suspect S. suis isolates, which showed alpha haemolysis on SBA and that 
were assessed to demonstrate morphology consistent with S. suis were sub-cultured onto 
fresh plates for isolation. Identification was carried out using matrix assisted laser desorption 
ionization-time of flight mass spectrometry (MALDI-TOF) typing (Bruker). Following 
confirmation, isolates were harvested from SBA plates into 1ml of Tryptic Soy Broth (TSB) 
+10% glycerol and stored at -80°C in sterile microcentrifuge tubes. A random subset of 
isolates was thawed and streaked on to SBA for resurrection at 37°C. Purity of each isolate 
was confirmed prior to harvesting plates onto transport swabs for postage to Murdoch 
University.  
MIC Testing.  
All isolates were subjected to antimicrobial susceptibility testing via broth microdilution 
according to the Clinical Laboratory Standards Institute (CLSI) Performance Standards. MIC 
results were categorized as susceptible, intermediate and resistant using the clinical 
interpretative criteria specified in CLSI performance standard VET01-S3 (CLSI, 2015a). If 













was used (CLSI, 2015b). Streptococcus pneumoniae ATCC 49619and Staphylococcus aureus 
ATCC 29213 were used as a control strains as per CLSI VET01-S3. 
 
Whole-genome sequencing. 
DNA extractions were performed on the 148 isolates using a MagMax DNA multi-sample kit 
(ThermoFisher Scientific) according to the manufacturer’s instructions, with the modification 
to omit the RNAse treatment step. Library preparation was performed with a Nextera XT kit 
with the only change from the manufacturer’s instructions being an increased tagmentation 
time of 7 minutes. Sequencing was performed on an Illumina Nextseq 500 platform using a 
mid-output V2 (2 x 150 cycles) reagent kit. 
Sequence analysis 
All sequencing files were uploaded to the Center for Genomic Epidemiology 
(http://www.genomicepidemiology.org/) and parsed through the Nullarbor bioinformatics 
pipeline (v1.20) (Seeman et al.) to determine MLST and antimicrobial resistance genes. A 
database was manually created containing all capsular serotypes and 40 previously described 
putative virulence genes (Segura et al., 2016). The Abricate (Nullarbor) programme was used 
to query contig files against the database to determine capsular type and virulence genes, with 
cutoffs of ≥95% coverage and ≥99% identity used to determine gene presence. 
Distinguishing serotype 2 from serotype 1/2, and serotype 1 from serotype 14 was performed 
as outlined by Athey et al. (2016a). Analysis of mrp and epf variants was based on in-silico 
analysis of sequences as per previously published data (Silva et al., 2006; Wisselink et al., 
2002). 
Phylogenetic trees were constructed based on single nucleotide polymorphisms (SNPs) in the 













published sequences from Vietnamese, UK, North American and Canadian isolates (Athey et 
al., 2016b; Weinert et al., 2015) were downloaded from NCBI and ENA. Genome annotation 
was performed using Prokka (v1.12) (Seemann, 2014) and outputs were processed using 
Roary (v3.8.0) (Page et al., 2015) for core genome determination and Gubbins (v2.2.3) 
(Croucher et al., 2015) for recombination removal and alignment. Manual annotation of trees 
was performed in iTOL (v4.2) (Letunic and Bork, 2016). Sequences for new MLST allele 
variations were uploaded to the Streptococcus suis MLST Databases site 
(https://pubmlst.org/ssuis/) for assignment of allele identification, and final allele 
combinations were then uploaded for assignment of new MLSTs. All sequence read data 




Genomic and phylogenetic analysis 
Genomic analysis of the 148 isolates revealed that 110 isolates belonged to 11 previously 
identified MLSTs with 38 isolates belonging to one of 26 newly identified MLSTs. The most 
prominent MLSTs were ST 27 (27/148), ST 25 (26/148), ST 28 (11/148), ST 483 (11/148) 
and ST 1 (10/148). The new MLSTs assigned in this study were ST 1031 – ST 1056 
inclusive.  
Analysis of the capsular genes resulted in two major serotypes being detected; serotype 2 
(39/148) and serotype 3 (37/148). The other main serotypes were 1/2 (11/148), 16 (8/148), 19 
(8/148), 8 (7/148) and 4 (7/148). Analysis of serotype and MLST combinations showed a 













serotype 2 ST28 (6.1%). Of serotypes where more than one isolate was present, serotype 15 
(n=2), 16 (n=8), 21 (n=4) and 31 (n=5) all had previously unidentified STs. 
The proportion of isolates carrying the main virulence factors mrp, epf or sly across all 
isolates was 7.4% (cps 1/2, 2, 14 and 19), 6.8% (cps 1/2, 2 and 14) and 33.1% (cps1/2, 2, 3, 
4, 5, 7, 8, 11, 12, 14, 15, 16, 18, 19, 21, and 23) respectively. Only a single isolate carried 
both mrp and sly, while 6.8% of isolates carried both mrp and epf, and 6.8% carried mrp, epf 
and sly. The isolates carrying all three genes belonged to serotypes 1/2 (n=7), 2 (n=2) and 14 
and all belonged to MLST 1, with a significant association between ST 1 and the carriage of 
all three genes (Fisher’s exact test P-value <0.0001). Although predominantly isolated from 
lung, two of these isolates originated from brain and two from joint fluid and all four of these 
isolates were serotype 1/2. These serotype 1/2 ST1 isolates also carried more of the examined 
putative virulence genes with an average of 46 compared to all other isolates carrying 36, and 
were clustered according to putative virulence gene content (Figure 1). All isolates carrying 
epf carried the short form of epf, also referenced as the EF protein in Wisselink et al. (2002). 
All mrp positive isolates carried a long form of mrp, ranging between 1128 and 1148 bp in 
length 
The main putative virulence genes present across all isolates included enolase (100%), 
GAPDH (100%), gdh (100%), luxS (100%), pgdA (100%), stk (100%), divIVA (99.3%), dltA 
(99.3%), dnaJ (99.3%), ef-tu (99.3%), ldh (99.3%), oatA (99.3%), srtA (99.3%) and ypfJ 
(99.3%). Detailed examination of the virulence gene profiles with the exclusion of common 
genes listed above demonstrates that the Australian isolates can be grouped in multiple clades 
based on putative virulence gene carriage (Figure 1). Of most significance was a single clade 
containing a conserved block of 32 putative virulence genes, which was the only group to 
contain the genes dppIV, epf, mrp, sbp2, oppA and lde. This group consisted predominantly 













On average, the total gene content of systemic isolates from brain and joint, was 2057, 
significantly lower than that from respiratory isolates which carried 2109 (Mann-Whitney U 
test p-value = 0.025). When isolates from brain, joint, heart and abdomen were analysed, the 
average total gene content was 2095, which was not significantly different from respiratory 
isolates (p-value=0.682). When the total gene content of isolates was compared to the number 
of putative virulence genes a trend was observed based upon ST (Figure 2a). This was most 
apparent in the ST1 isolates which had a significantly higher number of putative virulence 
genes compared to the other ST’s, and the lowest average total gene content of 1918 (p-
value<0.00001). These findings were mirrored by an assessment of global S. suis virulence 
genes against total gene content (Figure 2b). Most striking is the consistent clustering of ST1 
isolates with a mean putative virulence gene content of 45.8 and a mean total gene content of 
1936. The six non-ST1 isolates within this cluster consist of ST107 (n=1), ST105 (n=2) and 
ST144 (n=3) which are single locus variants (SLV) of ST1. Additionally, for the published 
systemic isolates from Weinert et al. (2015), from which data was analysed and MLST able 
to be determined using the Nullarbor pipeline, 51/108 (47.2%) were ST1, with the next 
highest proportion being ST28 at 17/108. When SLVs were analysed, another seven isolates 
were found to be variants at the gki locus, such that when ST1 and ST1 SLV isolates were 
combined they accounted for 53.7% of systemic isolates. 
Phylogenetic comparison of the S. suis isolated from Australian pigs against a global 
collection of S. suis strains resulted in the identification of four major clades (Figure 3). The 
strains from this study were present in all four clades. Clade 1 was highly divergent from the 
other clades, and contained 20 Australian strains, with strain 74-1662 (serotype 12 ST87), an 
isolate from lung tissue, being the most divergent. The majority of the Australian strains 
(89/148) clustered in clade 2, which was comprised entirely of strains from the UK, North 













Vietnamese and UK isolates. Australian serotype 2 ST25 isolates clustered with Canadian 
and North American serotype 2 ST25 isolates within clade 2. To explore this relationship, 
further analysis of the core genome was performed on these isolates (Figure 4). While 
Australian isolates could be distinguished from North America and Canadian strains, the 
small SNP difference was notable, as aside from isolate 60-154, Canadian and Australian 
isolates differed by a maximum of only 100 SNPs across the core genome.  
Antimicrobial susceptibility testing 
All 148 isolates were subjected to micro-broth dilution to determine the MIC value against 
ten antibiotics belonging to eight classes (Table 2). A high proportion of the isolates were 
resistant to both tetracycline (99.3%) and erythromycin (83.8%). Low levels of resistance 
were observed for florfenicol (14.9%), penicillin G (8.1%), ampicillin (0.7%) and 
trimethoprim/ sulphamethoxazole (0.7%). None of the isolates were resistant to enrofloxacin. 
Among the S. suis isolates, 15.6 % were multi-drug resistant (MDR; resistance to ≥3 classes 
of antimicrobial) (Table 3). Commonly identified MDR phenotypes included 
macrolide/phenicol/tetracycline (7.4%) and β-lactam/macrolide/tetracycline (6.1%). All 
isolates carried resistance against at least one antimicrobial class with 73.7% resistant to two 
classes of antimicrobial. The most common phenotypic profile was resistance to a 
combination of macrolides and tetracyclines with 67.6% of isolates determined to carry this 
resistance. When analysed by serotype using a Fisher’s exact test there was no significant 
association between serotype and AMR phenotype. This lack of association was also seen 
when systemic isolates alone were assessed. 
The two dominant antimicrobial resistance genes detected in these isolates were tetO and 
ermB. The percentage of isolates carrying identified resistance genes for tetracyclines 













being resistant to tetracyclines and macrolides respectively. Other resistant genes present 
included aph(3’) (n=6), fexA (n=1), optrA (n=3), lnuB (n=6) and spc (n=5).  
 
Discussion 
Streptococcus suis is a major cause of disease in pigs, with the potential for significant public 
health impact. In this study we present a detailed assessment of S. suis isolates from clinically 
affected Australian pigs, and compare these isolates to internationally available genome 
sequence data. Key findings include the virulence potential of ST1 clones, the zoonotic 
disease potential of Australian ST1 clones which cluster with Vietnamese isolates from cases 
of human disease, the potential of ST1 bacterial adhesion factors as vaccine targets and the 
limited evolution of Australian clones from their global seed strains. 
Analysis of 148 Australian isolates determined that the majority were serotype 2 (26%) or 
serotype 3 (25%), followed by serotype 1/2 (7.4%). This is consistent with global S. suis 
strains isolated from cases of disease, particularly for serotypes 2 and 3 in Canada, North 
America and China (Goyette-Desjardins et al., 2014). While the majority of isolates were 
obtained from lungs, 32 isolates were obtained from brain, abdomen, heart or joint, 
suggesting invasive or systemic isolates. Of these, 13 were serotype 2 and six were serotype 
1/2. However given this relatively small sample size of systemic isolates , and the fact the 
association between serotype and site of isolation was not significant when assessed by 
systemic isolates (Fisher’s exact test p=0.07), an increased pathogenicity cannot necessarily 
be ascribed to these serotypes. Significantly, even within this sample set, there were 20 
individual serotypes detected (Supplementary Table 1).  
While ST27 and ST25 were the most prevalent MLSTs, 37 individual STs were identified, 













which documented four STs including 1, 25, 28 and 369 (Groves et al., 2015). The reason for 
this significant difference in MLSTs between Groves et al. (2015) and this study is unknown, 
but potentially due to a number of factors. Firstly, the previous study assessed 45 isolates, this 
study had over 100 more, increasing the likelihood of detecting other STs. Secondly, isolates 
from Groves et al. (2015) were all serotype 2, whereas 20 serotypes were detected here, again 
increasing the chances of identifying different STs. The prevalence of isolates as serotype 2 
ST25 (17.6%) and serotype 2 ST28 (6.1%) is consistent with those from North America, 
Canada, Germany, Spain, the United Kingdom and China, and serotype 3 ST27 (18.2%) is 
consistent with reports from Spain and the United Kingdom (Goyette-Desjardins et al., 2014). 
These findings indicate that capsular and ST combinations are stable and conserved, and it is 
likely that the circulating strains present in Australia are reflective of the seed stock which 
was imported from the United Kingdom, Canada and New Zealand (Todd, 1988). 
Despite conservation of serotype/ST combinations, the use of whole genome sequencing 
demonstrates geographic clustering at the level of the core genome. Analysis of Australian 
and international isolates demonstrates four clades, although more than 80% of the isolates 
are present in clades 2 and 4. Clade 2 consists of isolates from the United Kingdom, Canada 
and Australia. It can be seen that the Australian isolates form distinct clusters, which correlate 
with serotype/MLST combinations. Within clades however, the SNP differences are minor 
between Australian and international isolates, demonstrating very little evolutionary 
divergence. In Clade 2, Australian serotype 2 ST25 isolates (Fig 4 red) clustered within 
Canadian serotype 2 ST25 isolates (Fig 4 yellow). Re-deriving the core genome for these 
isolates showed two populations separated by geographic origin. Despite this separation, the 
level of evolutionary divergence has been remarkably low over a 30 year period, with most 
isolates from Australia and Canada separated by less than 100 nucleotide differences across 













stable, it nullifies our hypothesis that Australian isolates would form divergent populations 
which over time become phylogenetically distinct from the original clone. Only eight 
Australian isolates were present in clade 4, which otherwise consisted entirely of Vietnamese 
and UK isolates. These Australian isolates were all serotype 1/2 ST1, aside from a single 
isolate which was serotype 14 ST1. This appears to indicate that the MLST of S. suis is a 
better predictor of core genome phylogeny than the serotype. The presence of these isolates 
and their core genome similarity to the south-east Asian isolates could be due to a number of 
reasons. Historically, assays did not differentiate between serotypes 2 and 1/2, with isolates 
being reported as serotype 2 or serotype 2 (plus 1/2) (Smith et al., 1999). For this reason it 
may be that these isolates are derived from European serotype 1/2 isolates which were 
initially labelled as serotype 2. Another scenario is that a clinically normal swine worker 
from south-east Asia transmitted a precursor serotype 1/2 clone from the Asian region to 
Australian pigs, although the epidemiology and carriage in clinically unaffected humans is 
not well defined (Segura, 2009). Another factor to be considered is the interaction between 
wild birds, feral pigs and swine production systems. It has been shown that wild birds can be 
infected with S. suis, and the potential for wild bird species  to contaminate feed and water 
sources of pig production systems with salmonella has been shown (Devriese et al., 1994), 
indicating potential for a similar pathway of S. suis transmission (Andres-Barranco et al., 
2014). In addition, feral pigs could possibly harbour divergent strains of S. suis. Australia’s 
feral pig population inhabit regions frequented by wild birds, and may contract S. suis 
serotypes not commonly circulating in production herds. While the extent of feral pig 
interaction with commercial swine is unknown, there is evidence that feral pigs move in close 
proximity to some production enterprises (Pearson et al., 2014). 
There are an increasing number of virulence factors termed critical to virulent strains of S. 













different clones (Segura et al., 2017). Historically there has been a focus on three particular 
virulence factors; muraminidase-released protein (mrp), extracellular protein factor (epf) and 
suilysin (sly), shown to be associated with highly virulent strains, with cps2 strains carrying 
all three genes considered the most virulent globally (Oh et al., 2017). Analysis of Australian 
isolates revealed that serotype 2 and 3 isolates were almost exclusively mrp-/epf-/sly-. This is 
in agreement with early studies demonstrating that the presence of all three of these factors is 
not necessary for a clone to exhibit high levels of virulence (Smith et al., 1996), with 9/18 
(50%) of the isolates obtained from joints or brain having this gene combination. The 
presence of the mrp+/epf+/sly+ combination in 7/11 (63.6%) of serotype 1/2 isolates, along 
with 4/7 of these isolates being from joints or brain, indicates that Australian serotype 1/2 
isolates may have particular virulence potential, however a larger sample set, targeted to 
brain and joint isolates would be required to validate this. It was notable that serotype 1/2 
isolates were obtained from six separate farms and six separate production enterprises, 
indicating that this serotype is not confined to a single company or nucleus herd. The 
mrp+/epf+/sly+ combination was also carried by all ST1 isolates, and these were consistently 
the isolates with the largest array of putative virulence factors. Like serotype 1/2 isolates, ST1 
isolates were obtained from six farms and production enterprises. All epf+ strains carried the 
short form of epf, considered to be the most virulent of the epf subtypes (Smith et al., 1993). 
Additionally, all mrp subtypes were of standard length, resulting in 6.8% of isolates classified 
as epf+, mrp+,sly+ and 6.8% of isolates being classified epf+, mrp+,sly- ,a genotype which has 
been associated with virulence (Vecht et al., 1992). 
In the case of Australian ST1 isolates, a conserved constellation of virulence genes which 
was not present in other MLSTs provides some insight into the virulence of ST1 clones. Due 
to the low number of isolates in this clade (eight of known origin of which four were 













reliably inferred. While the majority of these genes have their potential virulence 
characteristics only defined in vitro, there is a distinct aggregation of bacterial adhesion 
factors such as fibronectin binding factors dpp IV, mrp, epf and sbp2 and oligopeptide 
binding protein oppA (Ge et al., 2009; Li et al., 2017; Yu et al., 2016; Zheng et al., 2018). 
The presence of ide, an IgM protease would also be involved in early phase infection and 
attachment to cells by cleaving IgM blocking cellular binding factors (Seele et al., 2013). 
When this gene block was investigated in ST1 clones from overseas, it was also found to be 
highly conserved across 226 isolates, with the exception of the oppA gene which was absent 
in 21.2% of isolates. Taken together these factors suggest that both Australian and 
international ST1 clones have a distinct fitness advantage in terms of binding ability towards 
host target cells, and ST1 bacterial adhesion factors may be a promising vaccine target.  
In order to determine if the potential virulence of Australian ST1 isolates could be classified 
by analysis of the GDH amino acid sequence, as had been reported in an overseas study, we 
compared of the amino acid sequence of GDH across the Australian strains (Kutz and 
Okwumabua, 2008). Further supporting the potential virulence, only ST1 isolates had amino 
acid substitutions of A, S, K and K in positions 296, 299, 305 and 330 respectively, the same 
combination of substitutions reported by Kutz et al. (2008) in highly virulent serotype 2 
clones.  
Studies have shown that virulent S. suis clones have smaller genome sizes combined with a 
larger number of virulence genes when compared with less virulent isolates (Weinert et al., 
2015). While the sample size of Australian isolates from sites other than the respiratory tract 
was too small to confirm this, the clustering of ST1 isolates as seen in Figure 2 clearly shows 
a high number of virulence genes in association with the lowest total gene content of all STs 













isolates which clearly demonstrated the same pattern, inclusive of six ST1 single locus 
variants. This data provides further evidence that ST1 clones worldwide carry high virulence 
gene content in combination with a low total number of genes and that virulence is more 
closely associated with MLST than cps type (Kerdsin et al., 2018).  
Antimicrobial resistance of Australian strains was similar to levels reported overseas with 
regards to tetracycline (99.3%), erythromycin (83.8 %) and trimethoprim/sulfamethoxazole 
(0.7%). Resistance to florfenicol was 14.9%, while all isolates were clinically susceptible to 
enrofloxacin, likely due to this being banned from use in food producing animals in Australia. 
Of concern was the observed clinical resistance to penicillin G, albeit at a relatively low level 
in 8.1% of isolates. This is a first line therapy for S. suis, and indeed the β-lactams are used in 
human therapy (Wertheim et al., 2009). Therefore this is an aspect of S. suis in Australia that 
must be carefully monitored from both an animal and public health point of view. There was 
no statistically significant association between serotype and resistance profile. This is likely 
due to the extended number of serotypes with low numbers of observations, greatly reducing 
the power of statistical tests, however while some studies have demonstrated serotype 
associated resistance profiles (Marie et al., 2002; Wisselink et al., 2006), others have not 
found a clear difference (Han et al., 2001; Soares et al., 2015). 
This study has greatly increased the data available on the circulating strains of S. suis in the 
Australian pig herd. Comparative genome analysis using Australian and overseas data 
revealed that production of autogenous vaccine stock should not be based totally on serotype 
of circulating strains. In fact it is our view that it is equally important to take into account 
MLST, as we have demonstrated that there is a strong correlation between MLST and 
putative virulence gene content. Additionally, the presence of bacterial adhesion factors 
associated with ST1 clones which were not present in other clonal groups also presents a 













In conclusion, our findings demonstrate that Australian clones of S. suis associated with 
clinical disease in pigs have maintained a stable core genome, mirroring the international 
seed-stock from which they were derived. Australian clones associated with disease in pigs 
consist predominantly of serotypes 2, 3 and 1/2, which is consistent with reports from other 
pig producing countries (Goyette-Desjardins et al., 2014). Despite the limited number, the 
characterisation of serotype 1/2 ST1 clones is significant, as all displayed distinctive factors 
associated with highly virulent S. suis, along with grouping separately to other Australian 
isolates in the Vietnamese/UK clade, potentially indicating a separate source of introduction. 
In addition to this, these strains have only low levels of divergence from Vietnamese and UK 
isolates from cases of swine and human systemic disease, making this a sequence type which 




Abraham, S., O'Dea, M., Page, S.W., Trott, D.J., 2017. Current and future antimicrobial 
resistance issues for the Australian pig industry. Anim Prod Sci 57, 2398-2407. 
Andres-Barranco, S., Vico, J.P., Garrido, V., Samper, S., Herrera-Leon, S., de Frutos, C., 
Mainar-Jaime, R.C., 2014. Role of wild bird and rodents in the epidemiology of 
subclinical salmonellosis in finishing pigs. Foodborne Pathog Dis 11, 689-697. 
Athey, T.B., Teatero, S., Lacouture, S., Takamatsu, D., Gottschalk, M., Fittipaldi, N., 2016a. 
Determining Streptococcus suis serotype from short-read whole-genome sequencing 













Athey, T.B., Teatero, S., Takamatsu, D., Wasserscheid, J., Dewar, K., Gottschalk, M., 
Fittipaldi, N., 2016b. Population Structure and Antimicrobial Resistance Profiles of 
Streptococcus suis Serotype 2 Sequence Type 25 Strains. PLoS One 11, e0150908. 
CLSI 2015a. Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From 
Animals (VET01-S3) 3rd Edition (Clinical and Laboratory Standards Institute). 
CLSI 2015b. Performance Standards for Antimicrobial Susceptibility Testing; (M100-S25). 
25th Informational Supplement. . 
Croucher, N.J., Page, A.J., Connor, T.R., Delaney, A.J., Keane, J.A., Bentley, S.D., Parkhill, 
J., Harris, S.R., 2015. Rapid phylogenetic analysis of large samples of recombinant 
bacterial whole genome sequences using Gubbins. Nucleic Acids Res 43, e15. 
Devriese, L.A., Haesebrouck, F., de Herdt, P., Dom, P., Ducatelle, R., Desmidt, M., Messier, 
S., Higgins, R., 1994. Streptococcus suis infections in birds. Avian Pathol 23, 721-
724. 
Ge, J., Feng, Y., Ji, H., Zhang, H., Zheng, F., Wang, C., Yin, Z., Pan, X., Tang, J., 2009. 
Inactivation of dipeptidyl peptidase IV attenuates the virulence of Streptococcus suis 
serotype 2 that causes streptococcal toxic shock syndrome. Curr Microbiol 59, 248-
255.  
Gottschalk, M. 2011. In: Zimmerman JJ, R.A., Schwartz JK, Stevenson G (Ed.) Diseases of 
Swine. Wiley Publishers, Iowa, 841-855. 
Goyette-Desjardins, G., Auger, J.P., Xu, J., Segura, M., Gottschalk, M., 2014. Streptococcus 
suis, an important pig pathogen and emerging zoonotic agent-an update on the 
worldwide distribution based on serotyping and sequence typing. Emerg Microbes 













Groves, M.D., Jordan, D., Chapman, T.A., Jassim, R.A., 2015. Multilocus sequence typing of 
Australian Streptococcus suis type 2 by MALDI-TOF mass spectrometry analysis of 
PCR amplicons. Vet Microbiol 177, 394-397. 
Han, D.U., Choi, C., Ham, H.J., Jung, J.H., Cho, W.S., Kim, J., Higgins, R., Chae, C., 2001. 
Prevalence, capsular type and antimicrobial susceptibility of Streptococcus suis 
isolated from slaughter pigs in Korea. Can J Vet Res 65, 151-155. 
Huong, V.T., Ha, N., Huy, N.T., Horby, P., Nghia, H.D., Thiem, V.D., Zhu, X., Hoa, N.T., 
Hien, T.T., Zamora, J., Schultsz, C., Wertheim, H.F., Hirayama, K., 2014. 
Epidemiology, clinical manifestations, and outcomes of Streptococcus suis infection 
in humans. Emerg Infect Dis 20, 1105-1114. 
Kennedy, K.J., Jadeer, A.A., Ong, C.W., Senanayake, S.N., Collignon, P.J., 2008. Two cases 
of Streptococcus suis endocarditis in Australian piggery workers. Med J Aust 189, 
413. 
Kerdsin, A., Akeda, Y., Takeuchi, D., Dejsirilert, S., Gottschalk, M., Oishi, K., 2018. 
Genotypic diversity of Streptococcus suis strains isolated from humans in Thailand. 
Eur J Clin Microbiol Infect Dis 37, 917-925. 
Kutz, R., Okwumabua, O., 2008. Differentiation of highly virulent strains of Streptococcus 
suis serotype 2 according to glutamate dehydrogenase electrophoretic and sequence 
type. J Clin Microbiol 46, 3201-3207. 
Letunic, I., Bork, P., 2016. Interactive tree of life (iTOL) v3: an online tool for the display 
and annotation of phylogenetic and other trees. Nucleic Acids Res 44, W242-245. 
Li, Q., Fu, Y., Ma, C., He, Y., Yu, Y., Du, D., Yao, H., Lu, C., Zhang, W., 2017. The non-
conserved region of MRP is involved in the virulence of Streptococcus suis serotype 













Marie, J., Morvan, H., Berthelot-Hérault, F., Sanders, P., Kempf, I., Gautier-Bouchardon, 
A.V., Jouy, E., Kobisch, M., 2002. Antimicrobial susceptibility of Streptococcus suis 
isolated from swine in France and from humans in different countries between 1996 
and 2000. J Antimicrob Chemother 50, 201-209. 
Mwaniki, C.G., Robertson, I.D., Trott, D.J., Atyeo, R.F., Lee, B.J., Hampson, D.J., 1994. 
Clonal analysis and virulence of Australian isolates of Streptococcus suis type 2. 
Epidemiol Infect 113, 321-334. 
Oh, S.I., Jeon, A.B., Jung, B.Y., Byun, J.W., Gottschalk, M., Kim, A., Kim, J.W., Kim, H.Y., 
2017. Capsular serotypes, virulence-associated genes and antimicrobial susceptibility 
of Streptococcus suis isolates from pigs in Korea. J Vet Med Sci 79, 780-787. 
Page, A.J., Cummins, C.A., Hunt, M., Wong, V.K., Reuter, S., Holden, M.T., Fookes, M., 
Falush, D., Keane, J.A., Parkhill, J., 2015. Roary: rapid large-scale prokaryote pan 
genome analysis. Bioinformatics 31, 3691-3693. 
Pearson, H.E., Toribio, J.A., Hernandez-Jover, M., Marshall, D., Lapidge, S.J., 2014. 
Pathogen presence in feral pigs and their movement around two commercial piggeries 
in Queensland, Australia. Vet Rec 174, 325. 
Seele, J., Singpiel, A., Spoerry, C., von Pawel-Rammingen, U., Valentin-Weigand, P., 
Baums, C.G., 2013. Identification of a novel host-specific IgM protease in 
Streptococcus suis. J Bacteriol 195, 930-940. 
Seeman, T., Bullach, D., Schultz, M., Kwong, J., Howden, B. Nullarbor. 
Seemann, T., 2014. Prokka: rapid prokaryotic genome annotation. Bioinformatics 30, 2068-
2069. 
Segura, M., 2009. Streptococcus suis: an emerging human threat. J Infect Dis 199, 4-6. 
Segura, M., 2015. Streptococcus suis vaccines: candidate antigens and progress. Expert Rev 













Segura, M., Calzas, C., Grenier, D., Gottschalk, M., 2016. Initial steps of the pathogenesis of 
the infection caused by Streptococcus suis: fighting against nonspecific defenses. 
FEBS Lett 590, 3772-3799. 
Segura, M., Fittipaldi, N., Calzas, C., Gottschalk, M., 2017. Critical Streptococcus suis 
Virulence Factors: Are They All Really Critical? Trends Microbiol 25, 585-599. 
Silva, L.M., Baums, C.G., Rehm, T., Wisselink, H.J., Goethe, R., Valentin-Weigand, P., 
2006. Virulence-associated gene profiling of Streptococcus suis isolates by PCR. Vet 
Microbiol 115, 117-127. 
Smith, H.E., Reek, F.H., Vecht, U., Gielkens, A.L., Smits, M.A., 1993. Repeats in an 
extracellular protein of weakly pathogenic strains of Streptococcus suis type 2 are 
absent in pathogenic strains. Infect Immun 61, 3318-3326. 
Smith, H.E., Vecht, U., Wisselink, H.J., Stockhofe-Zurwieden, N., Biermann, Y., Smits, 
M.A., 1996. Mutants of Streptococcus suis types 1 and 2 impaired in expression of 
muramidase-released protein and extracellular protein induce disease in newborn 
germfree pigs. Infect Immun 64, 4409-4412. 
Smith, H.E., Veenbergen, V., van der Velde, J., Damman, M., Wisselink, H.J., Smits, M.A., 
1999. The cps genes of Streptococcus suis serotypes 1, 2, and 9: development of rapid 
serotype-specific PCR assays. J Clin Microbiol 37, 3146-3152. 
Soares, T.C., Gottschalk, M., Lacouture, S., Megid, J., Ribolla, P.E., Pantoja, J.C., Paes, 
A.C., 2015. Streptococcus suis in employees and the environment of swine 
slaughterhouses in Sao Paulo, Brazil: Occurrence, risk factors, serotype distribution, 
and antimicrobial susceptibility. Can J Vet Res 79, 279-284. 
Tien le, H.T., Nishibori, T., Nishitani, Y., Nomoto, R., Osawa, R., 2013. Reappraisal of the 
taxonomy of Streptococcus suis serotypes 20, 22, 26, and 33 based on DNA-DNA 













Todd, A. 1988. The Australian Pig Industry-200 Years of Development In: The 1988 
Australian National Pig Fair, 69. 
Tramontana, A.R., Graham, M., Sinickas, V., Bak, N., 2008. An Australian case of 
Streptococcus suis toxic shock syndrome associated with occupational exposure to 
animal carcasses. Med J Aust 188, 538-539. 
Varela, N.P., Gadbois, P., Thibault, C., Gottschalk, M., Dick, P., Wilson, J., 2013. 
Antimicrobial resistance and prudent drug use for Streptococcus suis. Anim Health 
Res Rev 14, 68-77. 
Vecht, U., Wisselink, H.J., van Dijk, J.E., Smith, H.E., 1992. Virulence of Streptococcus suis 
type 2 strains in newborn germfree pigs depends on phenotype. Infect Immun 60, 
550-556. 
Weinert, L.A., Chaudhuri, R.R., Wang, J., Peters, S.E., Corander, J., Jombart, T., Baig, A., 
Howell, K.J., Vehkala, M., Valimaki, N., Harris, D., Chieu, T.T., Van Vinh Chau, N., 
Campbell, J., Schultsz, C., Parkhill, J., Bentley, S.D., Langford, P.R., Rycroft, A.N., 
Wren, B.W., Farrar, J., Baker, S., Hoa, N.T., Holden, M.T., Tucker, A.W., Maskell, 
D.J., Consortium, B.R.T., 2015. Genomic signatures of human and animal disease in 
the zoonotic pathogen Streptococcus suis. Nat Commun 6, 6740. 
Wertheim, H.F.L., Nghia, H.D.T., Taylor, W., Schultsz, C., 2009. Streptococcus suis: An 
Emerging Human Pathogen. Clin Infect Dis 48, 617-625. 
Wisselink, H.J., Joosten, J.J., Smith, H.E., 2002. Multiplex PCR assays for simultaneous 
detection of six major serotypes and two virulence-associated phenotypes of 
Streptococcus suis in tonsillar specimens from pigs. J Clin Microbiol 40, 2922-2929. 
Wisselink, H.J., Veldman, K.T., Van den Eede, C., Salmon, S.A., Mevius, D.J., 2006. 













seven European countries to antimicrobial agents licensed in veterinary medicine. Vet 
Microbiol 113, 73-82. 
Yu, Y., Qian, Y., Du, D., Xu, C., Dai, C., Li, Q., Liu, H., Shao, J., Wu, Z., Zhang, W., 2016. 
SBP2 plays an important role in the virulence changes of different artificial mutants 
of Streptococcus suis. Mol Biosyst 12, 1948-1962. 
Zheng, F., Shao, Z.Q., Hao, X., Wu, Q., Li, C., Hou, H., Hu, D., Wang, C., Pan, X., 2018. 
Identification of oligopeptide-binding protein (OppA) and its role in the virulence of 
Streptococcus suis serotype 2. Microb Pathog 118, 322-329. 
Table 1 Number of isolates and site of origin used in the study 






Lymph node 1 
Neck abscess 3 














Table 2 Distribution of minimum inhibitory concentrations for S. suis. 
drug 0.13 0.25 0.5 1 2 4 8 16 32 64 128 256 ns_ci cr_ci 
Ampicillin  99.3      .7     0.7(0,3.7) 0.7(0,3.7) 
  (147)      (1)       
Ceftriaxone  88.5 7.4 2 1.4     .7   . . 
  (131) (11) (3) (2)     (1)     
Ciprofloxacin  37.2 37.2 22.3 3.4        . . 
  (55) (55) (33) (5)          
Enrofloxacin 14.2 44.6 40.5 .7         0.7(0,3.7) 0(0,2.5) 
 (21) (66) (60) (1)           
Erythromycin 11.5 4.1 .7 1.4   2 1.4 79.1    84.5(77.6,89.9) 83.8(76.8,89.3) 
 (17) (6) (1) (2)   (3) (2) (117)      
Florfenicol    2 4.1 79.1 11.5  .7 1.4 .7 .7 93.9(88.8,97.2) 14.9(9.6,21.6) 
    (3) (6) (117) (17)  (1) (2) (1) (1)   
Gentamicin     6.1 40.5 43.2 9.5    .7 . . 
     (9) (60) (64) (14)    (1)   
PenicillinG 81.8 4.7 4.7 3.4 3.4  .7  .7    12.8(7.9,19.3) 8.1(4.3,13.7) 
 (121) (7) (7) (5) (5)  (1)  (1)      
Tetracycline    .7  .7 1.4 2 1.4 93.9   100 (97.5,100) 99.3(96.3,100) 
    (1)  (1) (2) (3) (2) (139)     
TMS   91.9 5.4 2  .7      8.1(4.3,13.7) 0.7(0,3.7) 
   (136) (8) (3)  (1)        
Percentage of isolates classified as non-susceptible (ns ci) and/or clinically resistant (cr ci) with corresponding 95% confidence intervals for 
those where breakpoints are available. Shaded areas indicate the range of dilutions evaluated. Vertical bars indicate clinical breakpoint (where 












Table 3 Phenotypic AMR profiles of Streptococcus suis isolated from Australian pigs. 
phenotype n % 
1: mac 1 0.7 
1: tet 15 10.1 
2: mac_tet 100 67.6 
2: phe_tet 9 6.1 
3: bla_mac_tet 9 6.1 
3: mac_phe_tet 11 7.4 
4: bla_fpi_mac_tet 1 0.7 
4: bla_mac_phe_tet 2 1.4 
Breakpoints used to classify isolates are clinical breakpoints. mac; macrolides, tet; 
tetracyclines, phe; phenicols, bla; beta lactams, fpi; folate pathway inhibitors. 
 
 
Figure 1: Presence of putative virulence factors in all 148 isolates from this study. Blocks 
indicate presence of individual genes. Genes are identified by columns and isolate number, 
the main and serotypes found in this study are identified in rows. The putative virulent clade 
(based upon carriage of genes) is highlighted, and mrp, epf and sly genes are coloured red. 
 
Figure 2. a) Total gene content of individual Australian isolates plotted against virulence 
factor content based on MLST. b) Total gene content of international isolates for which 














Figure 3. Core genome SNP phylogeny of Australian and international S. suis isolates. Pink 
labels encompass clade 1, purple labels encompass clade 2, blue labels encompass clade 3 
and green labels encompass clade 4. Yellow labels indicate Australian isolates. Orange fill 
encompasses Canadian/Nth American Serotype 2 ST25 and within this red fill encompasses 
Australian serotype 2 ST25. 
 
Figure 4. Serotype 2 ST25 isolate core genome SNP phylogeny. Red clade is Canadian/Nth 
American isolates, blue clade is Australian clade. Remainder are Australian divergent 
isolates. Scale indicates SNP differences. 
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